Clinical Trials Logo

Advanced Esophageal Cancer clinical trials

View clinical trials related to Advanced Esophageal Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT05425472 Recruiting - Clinical trials for Advanced Esophageal Cancer

A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer

Start date: July 27, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy, safety and pharmacokinetic characteristics of HR070803 in the treatment of advanced esophageal cancer.

NCT ID: NCT05174156 Recruiting - Clinical trials for Advanced Esophageal Cancer

Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

This study intends to explore the predictive biomarkers by Next-generation sequencing (NGS) and multiple immunohistochemistry (mIHC) for the treatment of SHR-1210 in combination with paclitaxel and platinum in advanced esophageal cancer.

NCT ID: NCT03706326 Recruiting - Clinical trials for Advanced Esophageal Cancer

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Start date: September 28, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The study is to assess the safety and efficacy of the immunotherapies using anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells in the treatment of patients with advanced esophageal cancer.

NCT ID: NCT03691090 Completed - Clinical trials for Advanced Esophageal Cancer

Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Start date: December 3, 2018
Phase: Phase 3
Study type: Interventional

This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of SHR-1210 + paclitaxel + cisplatin vs placebo+paclitaxel +cisplatin as 1L therapy for advanced esophageal cancer patients in China. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.